Effect of exogenous intravenous administrations of GLP-1 and/or GIP on circulating pro-atrial natriuretic peptide in subjects with different stages of glucose tolerance

Diabetes Care. 2015 Jan;38(1):e7-8. doi: 10.2337/dc14-1452.
No abstract available

Publication types

  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Intravenous
  • Aged
  • Atrial Natriuretic Factor / blood*
  • Diabetes Mellitus, Type 2 / blood*
  • Female
  • Gastric Inhibitory Polypeptide / administration & dosage*
  • Glucagon-Like Peptide 1 / administration & dosage*
  • Glucose Intolerance / drug therapy
  • Humans
  • Male
  • Middle Aged
  • Overweight / blood

Substances

  • Gastric Inhibitory Polypeptide
  • Atrial Natriuretic Factor
  • Glucagon-Like Peptide 1

Associated data

  • ClinicalTrials.gov/NCT00774488